Page last updated: 2024-12-06

terizidone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

terizidone: minor descriptor (1975-1984); on-line & Index Medicus search OXAZOLES (1975-1984); RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65720
CHEMBL ID2107553
CHEBI ID135278
SCHEMBL ID193690
MeSH IDM0262785

Synonyms (43)

Synonym
fmoc-d-3-(2-furyl)-alanine
terizidone (inn)
D07247
25683-71-0
terivalidin (tn)
terizidone
CHEBI:135278
4-[[4-[(3-oxo-1,2-oxazolidin-4-yl)iminomethyl]phenyl]methylideneamino]-1,2-oxazolidin-3-one
4,4'-[1,4-phenylenebis(methylidynenitrilo)]bis-3-isoxazolidinone
unii-1199lex5n8
terizidona [inn-spanish]
terizidone [inn]
1199lex5n8 ,
4,4'-(p-phenylenebis(methyleneamino))di-(isoxazolidin-3-one)
einecs 247-186-1
terizidonum [inn-latin]
terizidona
terizidonum
FT-0674867
CHEMBL2107553
AKOS025311219
SCHEMBL193690
terizidone [mart.]
terizidone [who-dd]
DB12954
4,4'-(1e,1'e)-(1,4-phenylenebis(methan-1-yl-1-ylidene))bis(azan-1-yl-1-ylidene)diisoxazolidin-3-one
BCP15839
DTXSID70905098
AS-16056
Q1318344
mfcd00866818
4,4'-(((1e,1'e)-1,4-phenylenebis(methanylylidene))bis(azanylylidene))bis(isoxazolidin-3-one)
C13574
4,4'-((1e,1'e)-(1,4-phenylenebis(methanylylidene))bis(azanylylidene))bis(isoxazolidin-3-one)
A911347
4,4'-[1,4-phenylenebis(methanylylideneazanylylidene)]di(1,2-oxazolidin-3-one)
6819-23-4
DTXSID30865245
EN300-22079234
4-[(e)-({4-[(e)-[(3-oxo-1,2-oxazolidin-4-yl)imino]methyl]phenyl}methylidene)amino]-1,2-oxazolidin-3-one
CS-0045228
HY-112324
AKOS040749632

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Azithromycin was not associated with excess serious adverse events (SAEs)."( Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
Butler-Laporte, G; Menzies, D; Winters, N, 2015
)
0.42

Pharmacokinetics

ExcerptReferenceRelevance
"7), and peak concentration was 38."( Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.
Court, R; de Vries, N; Gumbo, T; Harding, J; Maartens, G; McIlleron, H; Stewart, A; Wiesner, L, 2018
)
0.72

Dosage Studied

ExcerptRelevanceReference
"The aim of this study is to investigate the influence of hard capsule shells on the possibility of non-invasive monitoring and authentication of medicines presented in capsules dosage form."( Influence of the quality of capsule shell on the non-invasive monitoring of medicines using Terizidone as an example.
Balyklova, KS; Demkin, NA; Pomerantsev, AL; Rodionova, OY; Titova, AV, 2021
)
0.84
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (5.56)29.6817
2010's14 (77.78)24.3611
2020's3 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.47 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.45 (4.65)
Search Engine Demand Index61.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (10.53%)5.53%
Reviews3 (15.79%)6.00%
Case Studies1 (5.26%)4.05%
Observational0 (0.00%)0.25%
Other13 (68.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]